[THE INVESTOR] Green Cross announced on Aug. 4 that the efficacy and safety of its osteoarthritis treatment Shinbaro Capsules have been confirmed in phase 4 of clinical trials.

The anti-arthritis agent is manufactured from natural herbal extracts and was approved by the Korean Ministry of Food and Drug Safety in 2011. 





Phase 4 trials are conducted for additional data after receiving approval.

The pharmaceutical company reported in a thesis published in the latest issue of Journal of Ethnopharmacology that a total of 761 patients with degenerative arthritis took the prescription drug for 24 weeks and no one suffered from the abnormal reactions such as gastrointestinal perforation, blockade or bleeding.

The patients’ total WOMAC scale scores that measure pain, stiffness and function decreased 27.6 percent and visual analog scale also fell 16.9 percent, it added.

“Arthritis treatments in general cause gastrointestinal disorders and cannot be taken over a long period time but Shinbiro has been confirmed to be efficient and safe regardless of the prolonged intake,” said a Green Cross official.

By Hwang You-mee (glamazon@heraldcorp.com)